Tarsus Pharmaceuticals Ownership | Who Owns Tarsus Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Tarsus Pharmaceuticals Ownership Summary


Tarsus Pharmaceuticals is owned by 39.75% institutional investors, 3.07% insiders, and 57.18% retail investors. Blackrock is the largest institutional shareholder, holding 9.25% of TARS shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.99% of its assets in Tarsus Pharmaceuticals shares.

TARS Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockTarsus Pharmaceuticals39.75%3.07%57.18%
SectorHealthcare Stocks 35.58%11.87%52.55%
IndustryBiotech Stocks 35.75%11.83%52.41%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock3.27M9.25%$88.79M
Deep track capital, lp3.60M8.41%$252.54M
Blackrock funding, inc. /de3.55M8.30%$249.22M
Rtw investments, lp3.35M7.82%$234.72M
Cowen and company2.20M6.22%$59.72M
Paradigm biocapital advisors lp2.56M5.99%$179.74M
Vanguard group2.40M5.63%$196.48M
Janus henderson group2.24M5.24%$157.22M
Morgan stanley1.94M4.54%$136.39M
Jennison associates1.71M4.00%$120.11M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Tang capital management1.19M4.23%$83.38M
Deep track capital, lp3.60M4.12%$252.54M
Paradigm biocapital advisors lp2.56M3.67%$179.74M
Ally bridge group (ny)70.78K2.56%$4.21M
Cutter capital management, lp112.50K2.55%$6.23M
Rtw investments, lp3.35M2.34%$234.72M
Ghost tree capital235.00K2.00%$6.39M
Bioimpact capital329.75K1.79%$23.13M
Cowen and company2.20M1.64%$59.72M
Tri locum partners lp119.26K1.63%$7.09M

Top Buyers

HolderShares% AssetsChange
Blackrock3.27M0.00%614.03K
Deep track capital, lp3.60M4.12%595.97K
Millennium management564.58K0.02%447.57K
Janus henderson group2.24M0.08%310.64K
Vanguard fiduciary trust272.74K0.00%272.74K

Top Sellers

HolderShares% AssetsChange
Macquarie group---833.44K
Vivo capital---565.55K
Adage capital partners gp---543.00K
Jennison associates1.71M0.08%-517.95K
Invesco742.50K0.01%-269.86K

New Positions

HolderShares% AssetsChangeValue
Vanguard fiduciary trust272.74K0.00%272.74K$19.13M
Braidwell lp265.71K0.62%265.71K$18.64M
Vestal point capital, lp200.00K0.39%200.00K$14.03M
M&g166.36K0.06%166.36K$11.65M
Norges bank117.59K0.00%117.59K$9.63M

Sold Out

HolderChange
Turning point benefit group-2.00
Nelson, van denburg & campbell wealth management group-5.00
Capital performance advisors llp-5.00
Breakwater investment management-6.00
Signaturefd-7.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 2026162-35.20%17,007,525-61.39%390.37%79-42.34%60-29.41%
Dec 31, 2025158-29.15%24,700,440-44.97%570.52%84-21.50%52-41.57%
Sep 30, 202521710.15%44,818,3855.19%1051.05%105-17.32%8580.85%
Jun 30, 20252026.32%46,119,7906.86%1080.90%12730.93%49-30.99%
Mar 31, 2025193-3.02%43,559,2058.22%1101.01%100-16.67%7129.09%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv1.29M2.99%4.66K
Vanguard US Total Market Shares ETF1.14M2.73%-
iShares Russell 2000 ETF929.16K2.16%7.85K
Macquarie Small Cap Growth C478.19K1.13%-73.10K
Invesco Small Cap Value A457.84K1.09%-51.75K
Vanguard Institutional Extnd Mkt Idx Tr440.58K1.02%5.10K
PGIM Jennison Small Company A440.54K1.02%5.79K
Jennison SMid Cap Core Equity434.75K1.02%-78.07K
Lord Abbett Developing Growth A420.04K0.98%-
RTW Biotech Opportunities Ord401.31K0.96%401.31K

Recent Insider Transactions


DateNameRoleActivityValue
Mar 20, 2026Neervannan Seshadri Chief Operating OfficerSell$199.52K
Mar 19, 2026Whitfield Dianne C. Chief Human Resources OfficerSell$279.66K
Mar 18, 2026Whitfield Dianne C. Chief Human Resources OfficerSell$279.72K
Mar 17, 2026Whitfield Dianne C. Chief Human Resources OfficerSell$279.69K
Mar 17, 2026Wahl Bryan General CounselSell$283.51K

Insider Transactions Trends


DateBuySell
2026 Q1-29
2025 Q4-9
2025 Q3-3
2025 Q2-3
2025 Q1-19

TARS Ownership FAQ


Who Owns Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals shareholders are primarily institutional investors at 39.75%, followed by 3.07% insiders and 57.18% retail investors. The average institutional ownership in Tarsus Pharmaceuticals's industry, Biotech Stocks , is 35.75%, which Tarsus Pharmaceuticals exceeds.

Who owns the most shares of Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals’s largest shareholders are Blackrock (3.27M shares, 9.25%), Deep track capital, lp (3.6M shares, 8.41%), and Blackrock funding, inc. /de (3.55M shares, 8.30%). Together, they hold 25.97% of Tarsus Pharmaceuticals’s total shares outstanding.

Does Blackrock own Tarsus Pharmaceuticals?

Yes, BlackRock owns 9.25% of Tarsus Pharmaceuticals, totaling 3.27M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 88.79M$. In the last quarter, BlackRock increased its holdings by 614.03K shares, a 23.15% change.

Who is Tarsus Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Tang capital management is Tarsus Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 4.23% of its assets in 1.19M Tarsus Pharmaceuticals shares, valued at 83.38M$.

Who is the top mutual fund holder of Tarsus Pharmaceuticals shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Tarsus Pharmaceuticals shares, with 2.99% of its total shares outstanding invested in 1.29M Tarsus Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools